A novel soluble guanylate cyclase activator, avenciguat, in combination with empagliflozin, protects against renal and hepatic injury in diabetic

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Yufeng Huang, Wenjin Liu, Connor Outtrim, Michael P Pieper, Glenn A Reinhart, Nisha Sharma, Anna Tang, Xiao-Qing E Tsai, Zhou Wang

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: United States : American journal of physiology. Endocrinology and metabolism , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 642412

Thêm vào giỏ Liên kết toàn văn

Diabetic complications are linked to oxidative stress, which hampers the cyclic guanosine monophosphate production by inhibiting nitric oxide/soluble guanylate cyclase (sGC) signaling. This study aimed to determine whether the administration of a novel sGC activator avenciguat alone or in combination with an SGLT2 inhibitor could slow the progression of renal and liver fibrosis in the type 2 diabetic and uninephrectomized

Tạo bộ sưu tập với mã QR